Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review.

Q3 Medicine

Human Antibodies Pub Date : 2022-05-27 DOI:10.3233/hab-211511

Hossein Pourmontaseri, Niloofar Habibzadeh, Sarina Entezari, F. Samadian, Shamim Kiyani, M. Taheri, A. Ahmadi, M. Fallahi, Farzad Sheikhzadeh, Arina Ansari, Amirhossein Tamimi, N. Deravi

{"title":"Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review.","authors":"Hossein Pourmontaseri, Niloofar Habibzadeh, Sarina Entezari, F. Samadian, Shamim Kiyani, M. Taheri, A. Ahmadi, M. Fallahi, Farzad Sheikhzadeh, Arina Ansari, Amirhossein Tamimi, N. Deravi","doi":"10.3233/hab-211511","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nAcute lymphocytic leukemia (ALL) is a type of blood cancer that is more prevalent in children. Several treatment methods are available for ALL, including chemotherapy, upfront treatment regimens, and pediatric-inspired regimens for adults. Monoclonal antibodies (Mabs) are the novel Food and Drug Administration (FDA) approved remedies for the relapsed/refractory (R/R) adult ALL. In this article, we aimed to review studies that investigated the efficacy and safety of Mabs on ALL.\n\n\nMETHODS\nWe gathered studies through a complete search with all proper related keywords in ISI Web of Science, SID, Scopus, Google Scholar, Science Direct, and PubMed for English language publications up to 2020.\n\n\nRESULTS\nThe most commonly studied Mabs for ALL therapies are CD-19, CD-20, CD-22, and CD-52. The best results have been reported in the administration of blinatumomab, rituximab, ofatumumab, and inotuzumab with acceptable low side effects.\n\n\nCONCLUSION\nAppling personalized approach for achieving higher efficacy is one of the most important aspects of treatment. Moreover, we recommend that the wide use of these Mabs depends on designing further cost-effectiveness trials in this field.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/hab-211511","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUND Acute lymphocytic leukemia (ALL) is a type of blood cancer that is more prevalent in children. Several treatment methods are available for ALL, including chemotherapy, upfront treatment regimens, and pediatric-inspired regimens for adults. Monoclonal antibodies (Mabs) are the novel Food and Drug Administration (FDA) approved remedies for the relapsed/refractory (R/R) adult ALL. In this article, we aimed to review studies that investigated the efficacy and safety of Mabs on ALL. METHODS We gathered studies through a complete search with all proper related keywords in ISI Web of Science, SID, Scopus, Google Scholar, Science Direct, and PubMed for English language publications up to 2020. RESULTS The most commonly studied Mabs for ALL therapies are CD-19, CD-20, CD-22, and CD-52. The best results have been reported in the administration of blinatumomab, rituximab, ofatumumab, and inotuzumab with acceptable low side effects. CONCLUSION Appling personalized approach for achieving higher efficacy is one of the most important aspects of treatment. Moreover, we recommend that the wide use of these Mabs depends on designing further cost-effectiveness trials in this field.

查看原文本刊更多论文

单克隆抗体治疗急性淋巴细胞白血病的文献综述。

背景:急性淋巴细胞白血病(acute lymphocytic leukemia, ALL)是一种常见于儿童的血癌。目前有几种治疗ALL的方法，包括化疗、前期治疗方案和针对成人的儿科方案。单克隆抗体(mab)是美国食品和药物管理局(FDA)批准的治疗复发/难治性(R/R)成人ALL的新药。在本文中，我们旨在回顾研究单抗治疗ALL的有效性和安全性。方法在ISI Web of Science、SID、Scopus、b谷歌Scholar、Science Direct和PubMed中检索到2020年之前的英文出版物，并对相关关键词进行完整检索。结果针对ALL治疗最常见的单克隆抗体是CD-19、CD-20、CD-22和CD-52。据报道，使用布利纳单抗、利妥昔单抗、奥图单抗和吲哚单抗的效果最好，副作用低。结论应用个性化治疗是提高疗效的重要途径之一。此外，我们建议这些单克隆抗体的广泛使用取决于在该领域设计进一步的成本效益试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Antibodies Medicine-Immunology and Allergy

CiteScore

3.50

自引率

0.00%

发文量

期刊介绍： Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology under a single, cohesive theme. This includes fundamental research, applied science and clinical applications. Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors. Immunoregulatory molecules, including T cell hybridomas, will also be featured.